Rivaroxaban Dosing in Patients with Impaired Renal Function

Standard Dosing by Renal Function

For patients with moderate renal impairment (CrCl 30-49 mL/min) and severe renal impairment (CrCl 15-29 mL/min), the American College of Cardiology recommends a rivaroxaban dose of 15 mg once daily, with close monitoring for the latter group 1, 2
For patients with normal or mild renal impairment (CrCl ≥50 mL/min), the recommended dose for atrial fibrillation stroke prevention is 20 mg once daily with food, and for VTE treatment and prevention, the dose is 15 mg twice daily for 3 weeks, then 20 mg once daily 3, 4

Renal function must be assessed at baseline and monitored periodically throughout treatment, with annual monitoring for patients with preserved renal function, and more frequent monitoring (2-3 times per year) for patients with moderate renal impairment (CrCl 30-50 mL/min) 3, 1, 2
More frequent monitoring is also recommended in elderly patients, as age and renal impairment commonly coexist 1

Rivaroxaban has approximately 33% renal clearance of the absorbed dose, with 65% non-renal clearance, which explains why dose adjustments are necessary but the drug remains usable in severe renal impairment 1, 2
The European Society of Cardiology notes that severe renal impairment (CrCl 15-29 mL/min) was an exclusion criterion in major clinical trials, and the FDA approval for use in this population is based on pharmacokinetic modeling, not on clinical outcome data 1
The American Heart Association warns that rivaroxaban is contraindicated with strong dual inhibitors of both CYP3A4 and P-glycoprotein, as these cause significant drug accumulation that compounds renal impairment effects 1, 4
The European Heart Journal recommends that the 15 mg and 20 mg doses must be taken with food to ensure adequate absorption, as bioavailability increases from 66% to 80-100% 2

The American College of Cardiology recommends 15 mg orally twice daily with food for 21 days for acute DVT or PE treatment, followed by 20 mg once daily with food for maintenance therapy 5
After 21 days, transition to 20 mg once daily with food for continued VTE treatment, which should continue for at least 6 months 5
After completing 6 months of initial therapy, consider dose reduction to 10 mg once daily for extended secondary prevention of recurrent VTE, which can be taken with or without food 5, 6

The American College of Cardiology distinguishes that the VTE maintenance dose must be 20 mg daily, NOT 15 mg daily, as was studied in the PIONEER-AF trial for atrial fibrillation patients undergoing PCI 5

The European Heart Rhythm Association recommends avoiding NOACs in severe renal dysfunction (CrCl <15 mL/min) and dialysis patients given lack of evidence 7

The American College of Cardiology warns against using 15 mg daily for VTE maintenance in patients with normal renal function, as this underdoses patients and increases recurrence risk 5

The American Society of Hematology recommends considering a dose reduction to 10 mg once daily for extended secondary prevention of recurrent VTE, which can be taken with or without food 8

Both the 15 mg and 20 mg doses of rivaroxaban MUST be taken with food to ensure adequate absorption, as bioavailability increases from 66% to 80-100% 9

The American College of Cardiology recommends a dose of 15 mg once daily with food for patients with CrCl 15-50 mL/min for stroke prevention in atrial fibrillation 10
For patients with both atrial fibrillation and acute venous thromboembolism, the American College of Cardiology recommends prioritizing the higher dose indicated, using the VTE treatment regimen (15 mg twice daily × 21 days, then 20 mg once daily) as thrombotic risks from acute VTE outweigh other considerations 11

Dose adjustment is based on creatinine clearance calculated using the Cockcroft-Gault formula with actual body weight, according to the American College of Cardiology 10